282 related articles for article (PubMed ID: 29064423)
1. Targeting PDK1 for Chemosensitization of Cancer Cells.
Emmanouilidi A; Falasca M
Cancers (Basel); 2017 Oct; 9(10):. PubMed ID: 29064423
[TBL] [Abstract][Full Text] [Related]
2. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
[TBL] [Abstract][Full Text] [Related]
5. A patent update on PDK1 inhibitors (2015-present).
Sestito S; Rapposelli S
Expert Opin Ther Pat; 2019 Apr; 29(4):271-282. PubMed ID: 30897008
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
8. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.
Ellwood-Yen K; Keilhack H; Kunii K; Dolinski B; Connor Y; Hu K; Nagashima K; O'Hare E; Erkul Y; Di Bacco A; Gargano D; Shomer NH; Angagaw M; Leccese E; Andrade P; Hurd M; Shin MK; Vogt TF; Northrup A; Bobkova EV; Kasibhatla S; Bronson RT; Scott ML; Draetta G; Richon V; Kohl N; Blume-Jensen P; Andersen JN; Kraus M
Cancer Res; 2011 Apr; 71(8):3052-65. PubMed ID: 21493594
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
12. Targeting PDK1 in cancer.
Raimondi C; Falasca M
Curr Med Chem; 2011; 18(18):2763-9. PubMed ID: 21568903
[TBL] [Abstract][Full Text] [Related]
13. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
14. Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma.
Sestito S; Daniele S; Nesi G; Zappelli E; Di Maio D; Marinelli L; Digiacomo M; Lapucci A; Martini C; Novellino E; Rapposelli S
Eur J Med Chem; 2016 Aug; 118():47-63. PubMed ID: 27123901
[TBL] [Abstract][Full Text] [Related]
15. NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization.
Monisha J; Padmavathi G; Roy NK; Deka A; Bordoloi D; Anip A; Kunnumakkara AB
Curr Pharm Des; 2016; 22(27):4173-200. PubMed ID: 27291284
[TBL] [Abstract][Full Text] [Related]
16. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
18. MiR-128b is down-regulated in gastric cancer and negatively regulates tumour cell viability by targeting PDK1/Akt/NF-κB axis.
Zhang L; Lei J; Fang ZL; Xiong JP
J Biosci; 2016 Mar; 41(1):77-85. PubMed ID: 26949090
[TBL] [Abstract][Full Text] [Related]
19. Induction of Akt activity by chemotherapy confers acquired resistance.
Huang WC; Hung MC
J Formos Med Assoc; 2009 Mar; 108(3):180-94. PubMed ID: 19293033
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
